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Abstract:  The natural antibiotics CC-1065 and the duocarmycins are highly cytotoxic 
compounds which however are not suitable for cancer therapy due to their general toxicity. 
We have developed glycosidic prodrugs of seco-analogues of these antibiotics for a 
selective cancer therapy using conjugates of glycohydrolases and tumour-selective 
monoclonal antibodies for the liberation of the drugs from the prodrugs predominantly at 
the tumour site. For the determination of structure activity relationships of the different 
seco-drugs, experiments addressing their interaction with synthetic DNA were performed. 
Using electrospray mass spectrometry and high performance liquid chromatography, the 
experiments revealed a correlation of the stability of these drugs with their cytotoxicity in 
cell culture investigations. Furthermore, it was shown that the drugs bind to AT-rich 
regions of double-stranded DNA and the more cytotoxic drugs induce DNA fragmentation 
at room temperature in several of the selected DNA double-strands. Finally, an explanation 
for the very high cytotoxicity of CC-1065, the duocarmycins and analogous drugs is given.  
Keywords: ADEPT; anticancer agents; cancer therapy; CC-1065; cytotoxicity; DNA 
alkylation; duocarmycins; electrospray mass spectrometry; HPLC; oligonucleotides; 
structure activity relationship 
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1. Introduction  
The natural antibiotics CC-1065 (1, Figure 1) and the duocarmycins such as duocarmycin SA (2) 
are highly cytotoxic compounds and several derivatives of these natural products have already entered 
clinical trials [1–4]. Unfortunately, however, the general toxicity of these drugs is very high since their 
selectivity for tumour cells is rather low. The mode of action of the natural products as well as of 
related toxins is supposed to involve a sequence selective alkylation of cellular DNA in AT-rich 
regions that induces cell death [3–5]. 
Figure 1. (+)-CC-1065 (1) and (+)-duocarmycin SA (2) with highlighted pharmacophoric units. 
HN
N
O N
H
O
OH
OMe
N
O
NH
N
OH
OMe
H2N
O
1: (+)-CC-1065
IC50 = 20 pM (L1210)
N
H
N
O
NH
O
OMe
2: (+)-Duocarmycin SA
IC50 =1 0p M( L 1 2 1 0 )
MeO2C
OMe
OMe
 
 
To overcome the insufficient selectivity of these compounds, we have developed glycosidic 
prodrugs such as 3a,  3b and 3c (Figure  2) [6–9]. The glycosidic bonds in 3a–c can be cleaved 
selectively at the tumour site by using a suitable monoclonal-antibody-glycohydrolase-conjugate (here 
β-D-galactosidase) that removes the sugar moiety to give the corresponding seco-drugs 4a–c. Due to 
the monoclonal-antibody, the conjugate binds to tumour-associated antigens, thus limiting the 
activation of the prodrugs to the tumour tissue [10,11]. The seco-drugs 4a–c as well as 4d cyclise 
rapidly with loss of HCl to give the corresponding drugs 5a–d which contain a spirocyclopropyl-
cyclohexadienone moiety similar to the one that can be found in the natural products 1  and  2 
(Figure 1). The alkylating moiety of 5c and 5d (R
1 = H), which is formed in situ, is the 1,2,9,9a-tetra-
hydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI) subunit developed by Boger et al. [12–15], 
whereas 5a and 5b (R
1 = Me) bear the methylated CBI subunit developed in our group [6,7]. 
Whereas prodrugs 3a, 3b and 3c showed an excellent selectivity in cell culture experiments with 
QIC50 (QIC50 = IC50 (prodrug)/IC50 (prodrug + enzyme)) values of 4800 (3a), 1100 (3b) and 3500 (3c) 
[6–8], compounds 3a and 3b exhibited a reduced stability when being incubated in cell culture media 
or phosphate buffer [16]. The obviously relatively easy replacement of the secondary chloro atom in 
3a and 3b by a hydroxyl group, which renders the prodrugs inactive, resulted in a half life of 
approximately 14  h for these prodrugs. In contrast, 3c  showed less then 1% of hydrolysis after 
incubation for 24 h at 37 °C in cell culture medium [8,17].  Toxins 2009, 1 
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Figure 2. Glycosidic prodrugs 3a–c, seco-drugs 4a–d and cyclisation of the latter under 
loss of HCl to give the drugs 5a–d as analogues of the natural products 1 and 2. 
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Investigations of the reactivity of 4a against synthetic models of potential cellular target molecules 
using electrospray ionisation Fourier transform ion cyclotron resonance mass spectrometry   
(ESI-FTICR MS) had shown a highly effective alkylation of double-stranded DNA by the drug 5a 
formed in situ from 4a [16,18]. In contrast, the reactivity of 5a against single-stranded DNA, double-
stranded RNA and the tripeptide glutathione was only low, suggesting that alkylation of double-
stranded DNA is the predominant mode of action of this kind of drugs [19]. Since the DNA alkylation 
of analogue drugs did not correlate quantitatively with their relative cytotoxicity, we assumed that 
parameters like differences in the sequence selectivity [20,21] or in the stability of the compounds 
under physiological conditions [22,23] might modulate their cytotoxicity. 
Here we describe investigations aiming at a better understanding of structure-activity relationships 
regarding this class of compounds. For these studies, the reactivity of the four seco-drugs 4a–d against 
ten different DNA oligonucleotides was investigated using electrospray ionisation Fourier transform 
ion cyclotron resonance (ESI-FTICR) mass spectrometry and high performance liquid chromatography 
(HPLC). 
2. Results and Discussion  
The cytotoxicity of the hydrochlorides of seco-drugs 4a–4d against human bronchial carcinoma 
cells of line A549 (Table 1) was determined using a modified tumour colony forming ability test as 
reported previously [6–9,24]. Toxins 2009, 1 
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Table 1. In vitro cytotoxicity of the hydrochlorides of seco-drugs 4a–d against human 
bronchial carcinoma cells of line A549. Cells were exposed to various concentrations of 
the test substance for 24 h at 37 °C; after 12 days of subsequent incubation the clone 
formation was compared to an untreated control assay and the relative clone forming rate 
was determined. IC50: Concentration required for 50% growth inhibition of target cells. 
seco-drug IC50 (pM) 
4a·HCl 750 
4b·HCl 800 
4c·HCl 26 
4d·HCl 14 
 
The seco-drugs 4c and 4d containing a hydrogen atom at the pharmacophoric unit (R
1 = H) were 
found to show a much higher cytotoxicity than their analogues 4a and 4b containing a methyl group 
(R
1 = Me) at the same position. This is presumably due to the fact that an attack of the cellular target, 
namely N3 of the nucleobase adenine, at the electrophilic cyclopropane moiety of the corresponding 
drugs 5a–d resulting in a subsequent formation of the corresponding DNA adducts, is less hindered in 
the absence of the sterically more demanding methyl group. Additionally, the lower hydrolytic 
stability of the drugs 5a and 5b bearing a methyl group decreases their concentration in cell culture 
media [16,17], which would lower the cytotoxicity of these drugs determined in cell culture assays. 
The different side chains (R
2) in 4a and 4b on the one hand and 4c and 4d on the other hand seem to 
have only a small influence on the drugs’ cytotoxicity since 4a and 4b as well as 4c and 4d, 
respectively, show cytotoxicities within the same order of magnitude. This is understandable because 
both side chains contain a tertiary amine and have approximately the same size. Denny et al. as well as 
Boger et al. have previously reported that substituents at C-5 of the DNA binding subunit, which are 
here represented by R
2, have a pronounced effect on the rate and efficiency of the DNA alkylation and 
the resulting biological potency of CC-1065 analogues [25–28], but the exact type of the substituent 
does not seem to be as important as its length.  
2.1. Investigations on the Reactivity and Sequence Selectivity of 4a–d against DNA Oligomers 
The reactivity and sequence selectivity of 4a–d against ten different synthetic double-stranded 
DNA oligomers (ds-1–ds-10) and against the synthetic single-stranded DNA oligonucleotide ON-1 of 
ds-1 (Figure  3) was investigated using ESI-FTICR MS in order to rationalise differences in the 
compounds’ cytotoxicities. 
An alkylation of the DNA oligonucleotides ON-1 and ON-2 by the drugs 5a–d results in the form-
ation of covalent adducts denoted by ON-1*a–d and ON-2*a–d, respectively (Figure  4). In the 
absence of suitable nucleophiles like DNA, the drugs are partially hydrolysed to give the inactive 
alcohols 6a–d. Toxins 2009, 1 
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Figure 3. Base sequences of the ten double-stranded DNA oligonucleotides used in the 
present study. Double-stranded DNA oligonucleotides are denoted with the praefix “ds-“. 
Oligonucleotides with lower molecular mass are denoted with the abbreviation “ON-1” 
and oligonucleotides with higher molecular mass with the abbreviation “ON-2”.  
A: Adenine, G: Guanine, C: Cytosine, T: Thymine. 
5'-d(CGG TCA ATT AGT CGC)-3'
ds-1
3'-d(GCC AGT TAA TCA GCG)-5'
5'-d(TCG CCG GTC AAT TAG)-3'
ds-2
3'-d(AGC GGC CAG TTA ATC)-5'
5'-d(CGC TGC  ATT AGT CGC)-3'
ds-3
3'-d(GCG ACG TAA TCA GCG)-5'
5'-d(CGC TCG  AAT TGG CGC)-3'
ds-4
3'-d(GCG AGC  TTA ACC GCG)-5'
5'-d(CGC GCT  AAA AGA CCG)-3'
ds-5
3'-d(GCG CGA TTT  T CT GGC)-5'
5'-d(CGG CAA TTA TTG  CCG)-3'
ds-6
(ON-1)
(ON-2) 3'-d(GCC GTT  AAT AAC GGC)-5'
5'-d(CCG GCT  ATT AGG CCG)-3'
ds-7
(ON-1)
(ON-2) 3'-d(GGC CGA TAA T CC GGC)-5'
5'-d(CCA TAA AGC TTT  TTG C)-3'
ds-8
(ON-1)
(ON-2) 3'-d(GGT ATT TCG AAA AAC G)-5'
5'-d(CGG CTT  ATA  TGA CCG)-3'
ds-9
(ON-1)
(ON-2) 3'-d(GCC GAA TAT  ACT GGC)-5'
5'-d(TGG CTG CGA GCA CCT)-3'
ds-10
(ON-1)
(ON-2) 3'-d(ACC GAC GCT CGT GGA)-5'
(ON-1)
(ON-2)
(ON-1)
(ON-2)
(ON-1)
(ON-2)
(ON-1)
(ON-2)
(ON-1)
(ON-2)
 
Figure 4. Reaction of the drugs 5a–d with the DNA oligonucleotides ON-1 or ON-2 under 
formation of the alkylated oligonucleotides ON-1*a–d and ON-2*a–d, respectively, or 
hydrolysis of the drugs to give the alcohols 6a–d. 
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For the mass spectrometric investigations, the hydrochlorides of seco-drugs 4a–d were incubated 
with the DNA oligonucleotides in water for 24  h at 25°C. The samples were then diluted with 
equivalent amounts of methanol and investigated directly by means of ESI-FTICR mass spectrometry 
without preliminary purification or enrichment of the products as described previously [16,18,19]. 
Covalent adducts were identified by comparison of calculated and found masses and alkylation 
positions were determined by identification of the characteristic fragment ions formed from the 
alkylated oligonucleotides applying capillary skimmer dissociation (CSD) [16,18,19,29–32]. 
If only one of the two oligonucleotides of the double-stranded DNA was alkylated, the percentage 
of alkylation of ON-1 or ON-2 was calculated based on the relative peak intensities of the Toxins 2009, 1 
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corresponding isotope peaks of the unreacted oligonucleotides of ON-1  and  ON-2  after 24  h of 
incubation as compared to the same ratio after 0 h of incubation. In case both oligonucleotides were 
alkylated, the preferred alkylation of one of the two oligonucleotides was determined based on the 
relative peak intensities of the covalent adducts. Analogously, if an oligonucleotide was alkylated in 
more than one position, the preferred binding site was determined based on the relative peak intensities 
of the respective characteristic fragment ions. The percentage of alkylation of the single-stranded 
oligonucleotide ON-1 of ds-1 was determined by calculating the ratio of the peak intensity of the 
covalent adduct as compared to the unmodified oligonucleotide.  
Figure 5. Base sequences of the ten double-stranded DNA oligonucleotides used in the 
present study with alkylation positions marked by underlines. Potential alkylation positions 
in the oligonucleotides are denoted with a superscript and differing nucleobases in the 
5'-direction of potential competing binding sites are marked in red. 
5'-d(CGG TCA ATT A10GT CGC)-3'
ds-1
3'-d(GCC AGT TAA T   CA GCG)-5'
5'-d(TCG CCG GTC AAT TA14G)-3'
ds-2
3'-d(AGC GGC CAG TTA AT   C)-5'
5'-d(CGC TGC  ATT A10GT CGC)-3'
ds-3
3'-d(GCG ACG TAA T   CA GCG)-5'
5'-d(CGC TCG  AAT TGG CGC)-3'
ds-4
3'-d(GCG AGC  TTA ACC GCG)-5'
5'-d(CGC GCT  AAA A10GA CCG)-3'
ds-5
3'-d(GCG CGA10 TTT  T CT GGC)-5'
5'-d(CGG CAA T T A9 TTG  CCG)-3'
ds-6
(ON-1)
(ON-2) 3'-d(GCC GTT  A9A8T AAC GGC)-5'
5'-d(CCG GCT    ATT A10GG CCG)-3'
ds-7
(ON-1)
(ON-2) 3'-d(GGC CGA10 TAA T CC GGC)-5'
5'-d(CCA TAA A7GC T TT  TTG C)-3'
ds-8
(ON-1)
(ON-2) 3'-d(GGT ATT T CG A7AA AAC G)-5'
5'-d(CGG C T  T   ATA9  TGA CCG)-3'
ds-9
(ON-1)
(ON-2) 3'-d(GCC GA11A10 TAT  ACT GGC)-5'
5'-d(TGG CTG CGA GCA CCT)-3'
ds-10
(ON-1)
(ON-2) 3'-d(ACC GAC GCT CGT GGA)-5'
(ON-1)
(ON-2)
(ON-1)
(ON-2)
(ON-1)
(ON-2)
(ON-1)
(ON-2)
(ON-1)
(ON-2)
 
 
Figure 5 and Table 2 show the results of the mass spectrometric investigations (as described above) 
in terms of the main alkylation site and the percentage of alkylation. In Figure 5, alkylation positions 
are denoted by underlines and important differences in the base sequence in the 5'-direction of 
potential competing binding sites of ON-1 as compared to ON-2 are marked in red. Notably, all drugs 
alkylated mainly the nucleobase adenine (A) in AT-rich DNA regions of at least four consecutive AT 
base pairs with the alkylated adenine situated at the 3'-end of this sequence. This sequence selectivity 
could also be observed for the natural products CC-1065 and duocarmycin SA [5] and the alkylation of 
the oligonucleotide ON-1 of ds-4 by the drug 5d is the only exception hereof. Furthermore, all drugs 
prefer the nucleobase adenine (A) over thymine (T) in the first, second and third position in the 5'-
direction of the binding site as is obvious from the preferred binding positions in the oligonucleotides 
ds-6, ds-7 and ds-8, respectively (Figure 5 and Table 3). Hence, the drugs preferably alkylate the 
oligonucleotides  ON-2 of these double-stranded oligonucleotides instead of the   
oligonucleotides ON-1. Toxins 2009, 1 
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Table 2. Alkylation efficiency and alkylation position after incubation of the DNA oligo-
nucleotides ds-1–ds-10 and ON-1 of ds-1 with the hydrochlorides of 4a–d in a 1:1 ratio for 
24 h at 25 °C. 
  Alkylation [%]  Alkylation position 
DNA  4a 4b 4c 4d  4a  4b  4c  4d 
ds-1  75 53 46 28  A
10 (ON-1) 
ds-2  60  66 9 31  A
14 (ON-1) 
ds-3  55 67 29 32  A
10 (ON-1) 
ds-4 – 
a – 
a – 
a 32  – 
b ON-1 
a
ds-5  ON-1 and ON-2 
c  6 A
10 (ON-1) ≥ A
10 (ON-2) A
10 (ON-1) 
ds-6  30 20 17 13  A
8 (ON-2) ≥ A
9 (ON-2) 
ds-7  ON-1 and ON-2 
c A
10 (ON-2) ≥ A
10 (ON-1) 
ds-8  ON-1 and ON-2 
c A
7 (ON-2) ≥ A
7 (ON-1) 
ds-9  77 82 21 30  A
10 (ON-2) ≥ A
11 (ON-2) 
ds-10 – 
a – 
a – 
a – 
a –
 b 
ON-1 of ds-1 20
  25
  – 
a – 
a –
 b 
a No significant amount of alkylation could be detected. 
b The alkylation position could not be 
determined due to the low abundance of the covalent alkylation product or of the specific fragments 
of the latter. 
c Since both oligonucleotides were alkylated, no percentage of alkylation could be 
determined. 
 
In addition, all drugs show a preference for purine bases (A or G) over pyrimidine bases (C or T) in 
the first position in the 3'-direction of the binding site. This results for example in the alkylation of A
8 
of ON-2 in ds-6 additionally to A
9 of the same DNA oligonucleotide (Figure 5, Table 3). 
Table 3. Prefered nucleobases in the vicinity of the alkylation position (0) as observed 
after incubation of the hydrochlorides of seco-drugs 4a–d with the DNA oligonucleotides 
ds-1–ds-10. 
 5'  4  3  2  1  0  –1  3' 
4a, 4c 
4b, 4d 
 
A/T > G/C 
G/C > A/T 
A > T  A > T  A > T  A  A/G > C/T   
 
Interestingly, the seco-drugs 4a and 4c containing a right hand dimethylamino-ethoxyindole subunit 
prefer AT base pairs in the fourth position in the 5'-direction of the binding site with the AT-rich 
sequence being located in the middle of the double strand. This is obvious due to the lower alkylation 
efficiencies of the double-strands ds-2 and ds-3 as compared to ds-1. In contrast, the seco-drugs 4b and 
4d containing a right hand morpholinoindole subunit prefer CG base pairs in the fourth position in the 
5'-direction of the binding site and AT-rich sequences located at the end of the double strand. This can 
be seen by the higher alkylation efficiencies of the double-strands ds-6 and ds-7 in comparison to ds-1. Toxins 2009, 1 
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Furthermore, all drugs showed a much higher reactivity against the double-stranded DNA oligo-
nucleotide ds-1 than against the respective single-stranded oligonucleotide ON-1 of ds-1 (Table 2). 
In summary, all drugs show a high selectivity for adenines in AT-rich DNA regions and differ only 
slightly in the preferred base sequence. Thus, differences in cytotoxicity are presumably not due to 
differences in sequence selectivity. Unexpectedly, also the alkylation efficiency regarding the same 
DNA oligonucleotide does not seem to correlate with the cytotoxicity of the drugs because, with the 
exception of ds-4, 4a and 4b alkylated the DNA with a significantly higher efficiency than the seco-
drugs 4c and 4d even though they show a lower cytotoxicity as observed in the cell culture assays than 
the latter (Table 2). 
2.2. Investigations on the Reaction Kinetics of the Seco-Drugs 
Consequently other factors seem to influence the biological activity of these alkylating agents and it 
could be argued that differences in the rate of the cyclisation reaction of the seco-drugs 4a–d to give 
the drugs 5a–d or maybe differences in the rate of formation of the DNA adducts might play a crucial 
role. Therefore, the hydrochlorides of seco-drugs 4a–d were incubated with the double-stranded DNA 
oligonucleotides in buffer or water for up to 24 h at 25 °C and the kinetics of the reactions were 
investigated using HPLC. Since covalent and non-covalent adducts of the DNA and the drugs elute 
with the same retention time under the conditions of these measurements [16], mixtures of both 
covalent and non-covalent adducts are denoted ds-x
(*
)a–d in the following whereas purely covalently 
bound adducts as detected by means of mass spectrometry are denoted ds-x*a–d. For evaluation, the 
area under the curve (AuC) in the HPLC chromatograms of the respective seco-drugs and their 
derivatives was determined based on their absorption of light at λ = 350 nm because at this wavelength 
the absorption of unmodified DNA can be neglected. It should be noted that the results obtained are 
only semi-quantitative, since we did not correct the calculated concentrations according to the molar 
extinction coefficients of the seco-drugs and their derivatives; however, it can be assumed that the 
extinction coefficients are approximately the same. Indeed, the results allow a good and straight-
forward comparison of the reactivity of the seco-drugs 4a–d and their drugs 5a–d, respectively. 
Figure 6 shows a series of HPLC chromatograms obtained at 0–4 h after starting the incubation of 
the hydrochloride of seco-drug 4a with ds-1 in phosphate buffer (pH 7). As can clearly be seen, the 
seco-drug cyclises to give the corresponding drug 5a very rapidly and the formation of the respective 
DNA-adduct ds-1
(*
)a has finished already after 2 h. Table 4 shows the resulting AuCs determined after 
up to 6 hours of incubation of a 1:1 mixture of the hydrochlorides of the seco-drugs 4a–d with the 
DNA in phosphate buffer (pH 7). 
The  seco-drugs  4a and 4b cyclise rapidly to give the corresponding drugs 5a and 5b which 
subsequently form the respective DNA adducts ds-1
(*
)a and ds-1
(*
)b within two hours. Hence, no free 
seco-drugs or drugs can be observed after two hours of incubation. In contrast, the more cytotoxic 
seco-drugs 4c and 4d cyclise to the corresponding drugs 5c and 5d with a much lower reaction rate 
and, moreover, the DNA adduct formation proceeds quite slowly. Thus, after six hours of incubation, 
DNA adduct formation is not completed and therefore, seco-drugs 4c and 4d can still be detected in 
considerable amounts. 
 Toxins 2009, 1 
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Figure 6. HPLC chromatograms (λ = 350 nm) obtained 0–4 h after starting the incubation 
of the hydrochloride of seco-drug 4a with ds-1 in phosphate buffer (pH 7). 
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Table 4. AuC after indicated times of incubation of the DNA oligonucleotide ds-1 with the 
the hydrochlorides of seco-drugs 4a–d in phosphate buffer (pH 7). 
  AuC [%] after the indicated time of incubation 
Reaction 
mixture 
Species  0 h  2 h  4 h  6 h 
ds-1/4a 
4a  78 –  –  – 
5a  22 –  –  – 
ds-1
(*
)a  – 100  100  100 
ds-1/4b 
4b  89 –  –  – 
5b  11 –  –  – 
ds-1
(*
)b  – 100  100  100 
ds-1/4c 
4c  74 45 19 12 
5c  26 20 14  – 
ds-1
(*
)c  – 35  67  88 
ds-1/4d 
4d  76 51 34 19 
5d  24 20 17 19 
ds-1
(*
)d  – 29  49  62 
 
Since seco-drugs such as 4a–d cyclise to the corresponding drugs nearly quantitatively in less than 
90 minutes in buffer without DNA [16,17], 4c and 4d obviously are stabilised by an interaction with 
the DNA. This interaction is relatively weak because it can be disrupted under conditions of chromato-
graphy to give back the free seco-drugs  4c  and 4d as well as unchanged DNA. In addition, the 
formation of stable non-covalent and covalent complexes of the respective drugs 5c and 5d with the Toxins 2009, 1 
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DNA oligonucleotides seems to be disfavoured because the amounts of ds-1
(*
)c ds-1
(*
)d increase only 
slowly and after prolonged incubation times, free drugs 5c (up to 4 h) and 5d (up to 6 h) can still be 
detected. Interestingly, the products of hydrolysis 6a–d are not observed, indicating that the rate of 
nucleophilic attack by water is reduced in the presence of DNA. 
Further, we investigated whether there might be differences in seco-drug stabilisation or DNA 
adduct formation correlating with the base sequence. Using again HPLC, the interaction of the four 
seco-drugs 4a–d with the DNA oligonucleotides ds-1–ds-10 was analysed. Tables 5 and 6 show the 
respective results obtained after 24  hours of incubation of a 1:1 mixture of DNA with the 
hydrochlorides of 4a–d in water at 25 °C. 
Table 5. AuC after 24 h of incubation of the DNA oligonucleotides ds-1–ds-10 with the 
hydrochlorides of seco-drugs 4a and 4b in water (pH 7). 
  ds-x/4a ds-x/4b 
ds-x  4a [%]  5a [%]  ds-x
(*
)a [%]  4b [%]  5b [%]  ds-x
(*
)b[%] 
ds-1 –  –  100  2  1  97 
ds-2 –  2  98  9  2  89 
ds-3 –  1  99  –  4  96 
ds-4 –  64  36  –  62  38 
ds-5 –  1  99  3  1  96 
ds-6 –  27  73  –  40  60 
ds-7 –  3  97  –  3  97 
ds-8 –  –  100  2  1  97 
ds-9 –  1  99  –  1  99 
ds-10 –  63  37  –  40  60 
 
After 24 hours of incubation, only traces (≤9%) of the seco-drugs  4a  and 4b were detected. 
Furthermore, with the exception of ds-4, ds-6 and ds-10, nearly all detectable amounts of the drugs 5a 
and 5b which had been formed during the time of incubation, were converted to the corresponding 
DNA adducts ds-x
(*
)a and ds-x
(*
)b, respectively. Additionally, even in those cases where only small 
amounts of DNA adduct were formed (ds-4, ds-6 und ds-10), no hydrolysis of the drugs 5a and 5b to 
the hydroxylated derivatives 6a and 6b (Figure 4) occurred in contrast to a notable hydrolysis of these 
drugs in the absence of DNA [16]. This indicates a weak interaction of the drugs with the DNA oligo-
nucleotides that stabilises the drugs against hydrolysis on the one hand, but disfavours the alkylation 
reaction on the other hand. Consistent with this observation, the formation of covalent adducts as 
determined by the mass spectrometric investigations is low regarding ds-4, ds-6 and ds-10. Toxins 2009, 1 
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Table 6. AuC after 24 h of incubation of the DNA oligonucleotides ds-1–ds-10 with the 
seco-drugs 4c and 4d in water (pH 7). 
  ds-x/4c ds-x/4d 
ds-x 
4c 
[%] 
5c 
[%] 
ds-x
(*
)c 
[%] 
DNA 
fragments 
[%] 
4d 
[%] 
5d 
[%] 
ds-x
(*
)d 
[%] 
DNA 
fragments 
[%] 
ds-1 1 –  99  –  45 3  52  – 
ds-2 13 –  87  –  17  2  81  – 
ds-3 8 –  92  –  19 3  78  – 
ds-4 15 68  17  –  19 68  13  – 
ds-5 59 –  41  –  63  3  34  – 
ds-6 4 13  53  30  27 8  48  17 
ds-7 3 11  73  13  7  2  84  7 
ds-8 5 –  95  –  30 3  67  – 
ds-9 2 –  83  15  21 3  70  6 
ds-10 29 53  18  –  33  41  26  – 
 
Notably, the effect of stabilisation of the seco-drugs and drugs by the DNA is much more pro-
nounced in the case of 4c and 4d as well as 5c and 5d, in comparison to that of 4a and 4b as well as 5a 
and 5b. Though in the absence of DNA all seco-drugs 4a–d cyclise quantitatively within 90 min in 
buffer or cell culture media [16,17], in the presence of DNA, the seco-drugs 4c and 4d cyclise to give 
the corresponding drugs 5c and 5d to a much lower extent than their methylated analogues 4a and 4b. 
Since the formation of the drugs is the prerequisite for the alkylation reaction, this might explain why 
the DNA alkylation is lower in case of 4c and 4d as compared to 4a and 4b. Interestingly, the extent of 
drug formation depends on the kind of double-stranded DNA oligonucleotide used, indicating a 
specific interaction of the seco-drugs with the DNA. The most pronounced stabilisation of the seco-
drugs can be observed using ds-5, in the presence of which only about 40% of 4c and 4d, respectively, 
are converted to the corresponding drugs in 24 hours. Nevertheless, with the exception of ds-4, ds-6, 
ds-10  and  partially also ds-7, most of 5c and 5d reacted with the DNA oligonucleotides under 
formation of the non-covalent and covalent DNA adducts ds-x
(*
)c and ds-x
(*
)d as was already found 
for 5a and 5b. However, additional DNA fragments indicative of strand cleavage could be observed in 
case of ds-6, ds-7 and ds-9 after incubation with 4c and 4d in contrast to the respective incubations 
with 4a and 4b. Figure 7 displays HPLC chromatograms showing the DNA fragmentation exemplarily 
for the reaction of seco-drugs 4c and 4d with the oligonucleotide ds-6. DNA was detected using a 
wavelength of λ = 260 nm and the seco-drugs 4c and 4d as well as all their derivatives including DNA 
adducts were detected using a wavelength of λ = 350 nm. As can clearly be seen, the drugs 5c and 5d 
induce cleavage of the intact DNA to form DNA fragments a part of which is still covalently bound to 
the drug. Toxins 2009, 1 
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Figure 7. HPLC chromatograms (λ = 260 nm  and λ = 350 nm)  of  ds-6 in water (Α), a 
solution of DNA oligonucleotide ds-6 incubated for 24 h with 4c·HCl in water (pH 7; B 
and D) and a solution of DNA oligonucleotide ds-6 incubated for 24 h with 4d·HCl in 
water (pH 7; C and E). 
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The high cytotoxicity of 4c and 4d might thus also be modulated by DNA strand cleavage. DNA 
lesions such as single- and double-strand breaks have been reported previously to be caused by 
analogues of CC-1065 and the duocarmycins such as adozelesin and bizelesin [33]. These damages 
can lead to cell death in case they cannot be repaired by the cellular repair machinery [34]. 
3. Experimental Section 
3.1. Materials 
The hydrochlorides of seco-drugs  4a–d were synthesised according to previously published   
procedures and stock solutions in DMSO were prepared [6–9]. The synthetic duplex-DNA oligomers  
ds-1–ds-10 and the single-stranded oligonucleotide ON-1 of ds-1 were purchased from IBA 
(Göttingen, Germany) as aqueous solutions (0.1 mM) of the sodium and ammonium salts, respectively. Toxins 2009, 1 
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The phosphate buffer (pH 7.0) was composed of Na2HPO4/NaH2PO4 (10 mM) and NaCl (0.1  M) in 
bidistilled water. 
3.2. Incubation of 4a–d with Synthetic DNA Oligonucleotides 
Incubations of the hydrochlorides of seco-drugs 4a–d with the double-stranded DNA oligonucleo-
tides ds-1 –10 and the single-stranded DNA oligonucleotide ON-1 of ds-1 were carried out in a 1:1 
ratio of seco-drug to DNA. For each experiment, an aliquot (1 µL, 5 nmol) of the stock solution of the 
respective seco-drug hydrochlorides in DMSO (5 mmol L
-1 4a–d) was mixed with an aliquot of DNA 
in water (50 µL, 5 nmol, 0.1 mmol L
-1 DNA). Either, the reaction mixture was incubated at 25 °C for 
24 h as such or phosphate buffer (pH 7, 50 µL) was added before starting the incubation. Samples 
were taken at different incubation times and analysed by means of mass spectrometry and 
chromatography.  
3.3. Electrospray Ionisation Fourier Transform Ion Cyclotron Resonance Mass Spectrometry   
(ESI-FTICR MS) 
For mass spectrometric investigations of the reaction mixtures, samples were taken at 0 h and 24 h, 
diluted with an equivalent amount of methanol and the resulting solution introduced directly into the 
ion source of the ESI-FTICR mass spectrometer. High-resolution mass spectrometry was performed 
using a 7 T-FTICR-MS instrument (APEX IV, Bruker Daltonics, Billerica, USA) equipped with an 
APOLLO electrospray ion source and a syringe pump (74900 series, Cole-Parmer, Vernon Hills, USA) 
with a flow rate of 2 µL min
-1 for sample injection. The ions were accumulated in the hexapole region 
for 0.8 s and transferred subsequently into the ICR cell. For gentle desolvatisation the drying gas 
temperature was set to 100 °C and the capillary exit voltage to –100 V. Enhanced fragmentation of 
alkylated oligonucleotides was achieved by capillary-skimmer dissociation (CSD) with a capillary exit 
voltage of –150 V. Ions were generated in the negative ion mode. 
3.4. High Performance Liquid Chromatography (HPLC) 
HPLC separations were performed with an Agilent 1200 with DAD from Agilent Technologies, an 
Aquapore OD-300 Column (220 × 4.6 mm, 7 µm) from Perkin Elmer and a Bondapak
® C18 Column 
(300 × 3.9 mm, particle size 10 µm, pore size 125 Å) from Waters. Samples were eluted within 45 min 
with a flow rate of 1  mL  min
-1 ( Aquapore OD-300) or 2 mL min
-1 (Bondapak
® C18) at 28  °C by 
applying a two-stage gradient (0–2 min: 5% B, 2–22  min: 5→20% B, 55–45  min: 20→80% B,   
45–50 min: 80% B, 50–60 min: 80→5% B). Eluent A: 0.1 mol L
-1 triethylammonium acetate buffer 
(H2O, pH  7.0). Eluent B: 0.1  mol  L
-1 triethylammonium acetate buffer (80% acetonitrile and 20% 
water, pH 7.0). The absorption of the drugs and their derivatives at λ = 350 nm was used to calculate  
the AuCs. 
4. Conclusions 
In summary, compounds 4c and 4d which are seco-analogues of the natural products CC-1065 and 
duocarmycin  SA, show a much higher cytotoxicity in cell culture investigations using a human Toxins 2009, 1 
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bronchial carcinoma cell line than the respective derivatives 4a and 4b containing a methyl group 
instead of hydrogen in the pharmacophoric unit. In order to understand the structure activity 
relationships underlying the differences in cytotoxicity, the reactivity of 4a–d against DNA as the 
proposed cellular target molecule was investigated by means of mass spectrometry and high 
performance liquid chromatography. 
The seco-drugs 4a–d form the respective drugs 5a–d in situ, and the latter act as DNA alkylating 
agents. The drugs show high affinity to AT-rich DNA sequences and alkylate adenines at the 3'-end of 
such sequences with high selectivity. All seco-drugs 4a–d are stabilised by the interaction with double 
stranded DNA oligonucleotides. This stabilisation delays the cyclisation reaction that gives the 
respective drugs 5a–d, and the effect is much more pronounced for seco-drugs 4c and 4d as compared 
to 4a and 4b. As a consequence, 4c and 4d are protected against hydrolytic deactivation and cyclise to 
the respective drugs 5c and 5d with a much lower reaction rate in the presence of DNA. In addition, 
the drugs 5c and 5d are less reactive than 5a and 5b and therefore alkylate double-stranded as well as 
single-stranded DNA much more slowly. The stability of the derivatives in the presence of DNA 
oligonucleotides correlates very well with the cytotoxicity of the compounds in cell culture 
investigations: The stronger the stabilisation of the seco-drugs and drugs by interaction with DNA 
oligonucleotides, the higher is their cytotoxicity. This observation is similar to results previously 
obtained by Boger et al. [35], in which a parabolic relationship between the cytotoxic potency of 
derivatives related to 5a–d and their stability against solvolysis was demonstrated. Furthermore, 5c 
and 5d seem to cause DNA fragmentation at room temperature whereas 5a and 5b do not. Based on 
our investigations, we assume that the mechanism responsible for the very high cytotoxicity of 
CC-1065, the duocarmycins and of related synthetic analogues is an over-stabilisation of the DNA 
double strand by non-covalent interactions, which prohibits the repair, transcription or replication of 
DNA and therefore induce apoptosis. In the literature, the cytotoxicity of CC-1065, the duocarmycins 
and related compounds is always explained by their alkylation properties. However, we think that the 
alkylation only serves for an irreversible fixation of the compounds in the minor groove of the DNA 
and the astounding base selectivity of the alkylation is only a question of proximity. Thus, the 
discussion that the adenine which is alkylated might be a so called hot spot explaining the very high 
cytotoxicity of these compounds compared to other alkylating drugs as cyclophosphamide is in our 
belief not meaningful anymore.  
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